Mo1215 Serum Golimumab Exposure and the Incidence of Selected Safety Events in Patients With Ulcerative Colitis Following Treatment With Golimumab: An Exploratory Analysis of the PURSUIT Study Data
Omoniyi J. Adedokun(Western University), William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Sam Liao, Hugh M. Davis(South College), Hongyan Zhang(Tianjin University), Zhenhua Xu(Hebei Medical University), Paul Rutgeerts(KU Leuven), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Walter Reinisch(Medical University of Vienna), Richard Strauß(Hennepin County Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Honghui Zhou(Janssen (United States))
Cited by 3
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k